Earnings ·
OnKure Therapeutics reported financial results for the quarter ended June 30, 2026
OKUROnKure Therapeutics, Inc.
OnKure Therapeutics reported financial results for the quarter ended June 30, 2026. The company held $176.4 million in cash and equivalents, providing a runway into 2029. Research and development expenses were $12.6 million, while general and administrative expenses rose to $4.3 million from $3.7 million in the prior year period. Net loss was $15.3 million, or $0.31 per share, compared to a net loss of $15.4 million, or $1.14 per share, in Q2 2025. The company continues IND-enabling activities for OKI-345 and OKI-355, with submissions planned for the first half of 2027. OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines targeting PI3Kα-driven diseases.